0000950170-25-059449.txt : 20250428 0000950170-25-059449.hdr.sgml : 20250428 20250428182204 ACCESSION NUMBER: 0000950170-25-059449 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250424 FILED AS OF DATE: 20250428 DATE AS OF CHANGE: 20250428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolph Timothy CENTRAL INDEX KEY: 0001779479 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 25882030 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY, 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2025-04-24 0001744659 Akero Therapeutics, Inc. AKRO 0001779479 Rolph Timothy 601 GATEWAY BOULEVARD SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Scientific Officer true Common Stock 2025-04-24 4 M false 6250 21.1 A 175971 D Common Stock 2025-04-24 4 S false 6250 41.03 D 169721 D Stock Option (Right to Buy) 21.1 2025-04-24 4 M false 2566 0 D 2031-12-07 Common Stock 2566 26152 D Stock Option (Right to Buy) 21.1 2025-04-24 4 M false 3684 0 D 2031-12-07 Common Stock 3684 25389 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.12, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2025-04-28